Clinical applications of B-type natriuretic peptide (BNP) testing.

[1]  A. Maisel.  Updated algorithms for using B-type natriuretic peptide (BNP) levels in the diagnosis and management of congestive heart failure. , 2002, Critical Pathways in Cardiology.

[2]  T. McDonagh,et al.  N-terminal brain natriuretic peptide: The new gold standard in predicting mortality in patients with advanced heart failure , 2003 .

[3]  TorbjørnOmland,et al.  N-Terminal Pro-B–Type Natriuretic Peptide and Long-Term Mortality in Acute Coronary Syndromes , 2002 .

[4]  J. Morrison.  Critical Pathways in Cardiology , 2002 .

[5]  U. Janssens,et al.  brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. , 2002, Journal of the American College of Cardiology.

[6]  J. Hollander,et al.  B-Type Natriuretic Peptide and Clinical Judgment in Emergency Diagnosis of Heart Failure: Analysis From Breathing Not Properly (BNP) Multinational Study , 2002, Circulation.

[7]  Alan S Maisel,et al.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.

[8]  M. Davies,et al.  Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations , 2002, BMJ : British Medical Journal.

[9]  M. Redfield,et al.  The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. , 2002, Journal of cardiac failure.

[10]  R. Berger,et al.  Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure. , 2002, European heart journal.

[11]  RudolfBerger,et al.  B-Type Natriuretic Peptide Predicts Sudden Death in Patients With Chronic Heart Failure , 2002 .

[12]  W. Kübler,et al.  Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure. , 2002, Journal of the American College of Cardiology.

[13]  A. DeMaria,et al.  Utility of B-Natriuretic Peptide in Detecting Diastolic Dysfunction , 2002 .

[14]  A. DeMaria,et al.  Utility of B-Natriuretic Peptide in Detecting Diastolic Dysfunction: Comparison With Doppler Velocity Recordings , 2002, Circulation.

[15]  B. Swynghedauw.  Susceptibility-conferring polymorphic genotypes in cardiovascular multifactorial syndromes. , 2002, European heart journal.

[16]  M. Vogeser,et al.  Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. , 2001, Journal of the American College of Cardiology.

[17]  P. Hildebrandt,et al.  Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations , 2001, European journal of heart failure.

[18]  A. Maisel,et al.  B-type natriuretic peptide in the diagnosis and management of congestive heart failure. , 2001, Cardiology clinics.

[19]  K. Bailey,et al.  Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. , 2001, Mayo Clinic proceedings.

[20]  M. Sabatine,et al.  The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. , 2001, The New England journal of medicine.

[21]  A. Maisel.  Practical approaches to treating patients with acute decompensated heart failure. , 2001, Journal of cardiac failure.

[22]  K. Swedberg,et al.  Guidelines for the diagnosis and treatment of chronic heart failure. , 2001, European heart journal.

[23]  E. Hartter,et al.  Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. , 2001, Journal of the American College of Cardiology.

[24]  R. Doughty,et al.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. , 2001, Journal of the American College of Cardiology.

[25]  N. Valli,et al.  Assessment of brain natriuretic peptide in patients with suspected heart failure: comparison with radionuclide ventriculography data. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[26]  P. Krishnaswamy,et al.  Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. , 2001, American heart journal.

[27]  P. Poole‐Wilson,et al.  Coronary artery disease as the cause of incident heart failure in the population. , 2001, European heart journal.

[28]  L. Lenert,et al.  A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. , 2001, Journal of the American College of Cardiology.

[29]  M. Vogeser,et al.  B-type natriuretic peptide (BNP)--validation of an immediate response assay. , 2001, Clinical laboratory.

[30]  A. Cowley,et al.  Failure of plasma brain natriuretic peptide to identify left ventricular systolic dysfunction in the community , 2000, Heart.

[31]  H. Hense,et al.  Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population , 2000, Journal of hypertension.

[32]  C. Frampton,et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.

[33]  D. Mant,et al.  Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: observational study , 2000, BMJ : British Medical Journal.

[34]  D. Murdoch,et al.  Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. , 1999, American heart journal.

[35]  M. Kinoshita,et al.  Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. , 1999, European heart journal.

[36]  G. Mariani,et al.  Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans. , 1999, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[37]  M. Niemelä,et al.  Plasma vasoactive peptides after acute myocardial infarction in relation to left ventricular dysfunction. , 1999, International journal of cardiology.

[38]  I. Squire,et al.  An immunoluminometric assay for N-terminal pro-brain natriuretic peptide: development of a test for left ventricular dysfunction. , 1999, Clinical science.

[39]  J. Sanderson,et al.  Plasma brain natriuretic peptide — an independent predictor of cardiovascular mortality in acute heart failure , 1999, European journal of heart failure.

[40]  R. Doughty,et al.  Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. , 1999, Circulation.

[41]  H. Hense,et al.  Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. , 1998, Journal of the American College of Cardiology.

[42]  J. McMurray,et al.  Cohort study of plasma natriuretic peptides for identifying left ventricular systolic dysfunction in primary care , 1998, BMJ.

[43]  C. Frampton,et al.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. , 1998, Circulation.

[44]  H. Tunstall-Pedoe,et al.  Biochemical detection of left-ventricular systolic dysfunction , 1998, The Lancet.

[45]  L. Thomas.  Clinical laboratory diagnostics : use and assessment ofclinical laboratory results , 1998 .

[46]  D. Gardner,et al.  N ATRIURETIC P EPTIDES , 1998 .

[47]  K. Jensen,et al.  Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. , 1998, The American journal of physiology.

[48]  P. Poole‐Wilson,et al.  Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care , 1997, The Lancet.

[49]  K. Nakao,et al.  Brain natriuretic peptide in an elderly population , 1997, Journal of internal medicine.

[50]  P. Ivarsen,et al.  A new, fast and reliable radioimmunoassay of brain natriuretic peptide in human plasma. Reference values in healthy subjects and in patients with different diseases. , 1997, Scandinavian journal of clinical and laboratory investigation.

[51]  D. Fukai,et al.  Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. , 1997, Circulation.

[52]  R. T. Lie,et al.  Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. , 1996, Circulation.

[53]  K. Nakao,et al.  Molecular biology and biochemistry of the natriuretic peptide system , 1996 .

[54]  E. J. Benjamin,et al.  Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. , 1995, Journal of the American College of Cardiology.

[55]  K. Nakao,et al.  Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure. , 1994, British heart journal.

[56]  C. Lang,et al.  Detection of left ventricular dysfunction after acute myocardial infarction: comparison of clinical, echocardiographic, and neurohormonal methods. , 1994, British heart journal.

[57]  K. Kugiyama,et al.  Localization and Mechanism of Secretion of B‐Type Natriuretic Peptide in Comparison With Those of A‐Type Natriuretic Peptide in Normal Subjects and Patients With Heart Failure , 1994, Circulation.

[58]  C. Lazzeri,et al.  Cardiovascular and renal effects of low dose brain natriuretic peptide infusion in man. , 1994, The Journal of clinical endocrinology and metabolism.

[59]  T. Horio,et al.  Serial changes in atrial and brain natriuretic peptides in patients with acute myocardial infarction treated with early coronary angioplasty. , 1993, American heart journal.

[60]  K. Nakao,et al.  Increased Plasma Levels of Brain Natriuretic Peptide in Patients With Acute Myocardial Infarction , 1993, Circulation.

[61]  A. Richards,et al.  Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. , 1993, British heart journal.

[62]  C. Frampton,et al.  Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. , 1993, The Journal of clinical endocrinology and metabolism.

[63]  C. Lang,et al.  Atrial and brain natriuretic peptides: a dual natriuretic peptide system potentially involved in circulatory homeostasis. , 1992, Clinical science.

[64]  R. Bonow,et al.  Left Ventricular Diastolic Dysfunction as a Cause of Congestive Heart Failure , 1992, Annals of Internal Medicine.

[65]  K. Nakao,et al.  Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors. , 1992, Journal of hypertension.

[66]  K. Nakao,et al.  Molecular biology and biochemistry of the natriuretic peptide system. I: Natriuretic peptides. , 1992, Journal of hypertension.

[67]  H. Imura,et al.  Hemodynamic, Renal, and Hormonal Responses to Brain Natriuretic Peptide Infusion in Patients With Congestive Heart Failure , 1991, Circulation.

[68]  H. Imura,et al.  Expression of Brain Natriuretic Peptide Gene in Human Heart: Production in the Ventricle , 1991, Hypertension.

[69]  K. Inouye,et al.  Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. , 1991, The Journal of clinical investigation.

[70]  J. Remes,et al.  Validity of clinical diagnosis of heart failure in primary health care. , 1991, European heart journal.

[71]  K. Nakao,et al.  Biosynthesis, secretion, and receptor selectivity of human brain natriuretic peptide. , 1991, Canadian journal of physiology and pharmacology.

[72]  H. Imura,et al.  Increased human brain natriuretic peptide in congestive heart failure. , 1990, The New England journal of medicine.

[73]  E. Espiner,et al.  Brain natriuretic peptide administered to man: actions and metabolism. , 1990, The Journal of clinical endocrinology and metabolism.